Lipid encapsulated cisplatin - Allarity Therapeutics /LiPlasome Pharma
Alternative Names: LiPlaCisLatest Information Update: 05 Jul 2023
At a glance
- Originator LiPlasome Pharma
- Developer Allarity Therapeutics; Cadila Pharmaceuticals; LiPlasome Pharma
- Class Antineoplastics; Platinum complexes; Small molecules
- Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Breast cancer; Prostate cancer
- Phase I/II Solid tumours
Most Recent Events
- 02 Jun 2023 Updated efficacy and adverse events data from the phase I/II LiPlaCis trial in Solid tumours presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 25 May 2023 Updated efficacy data from a phase I/II trial in Solid tumours released by Allarity Therapeutics
- 26 Oct 2020 Allarity Therapeutics receives patent allowance from the USPTO for Methods for predicting drug responsiveness in Cancer in the US